Common Hydroxychloroquine Drug Interactions

Hydroxychloroquine interacts with a surprisingly wide range of medications, mostly because it shares metabolic pathways with many common drugs and can affect the heart’s electrical rhythm. For the millions of people who take it long-term for lupus, rheumatoid arthritis, or other autoimmune conditions, these interactions matter in practical, everyday ways. The drug’s extremely long half-life means it lingers in the body for weeks after the last dose, so interactions can persist even after you stop taking it.

How Hydroxychloroquine Gets Processed and Why That Creates Problems

Your liver breaks down hydroxychloroquine using several enzymes from the cytochrome P450 family, primarily CYP2C8 and CYP3A4/5, with CYP2D6 also playing a role.¹ These same enzymes process hundreds of other medications. When hydroxychloroquine and another drug compete for the same enzyme, one or both can build up to higher-than-expected levels in the blood, or one can be cleared too quickly.

Hydroxychloroquine also interacts with drug transporters, which are proteins that shuttle medications into and out of cells. It inhibits P-glycoprotein (P-gp) at high enough concentrations and is itself a substrate of that transporter, meaning P-gp actively pumps it out of cells.² It also inhibits the transporter OATP1A2.¹ Drugs that rely on these same transporters to reach their targets or get eliminated can be affected when hydroxychloroquine is on board. The practical consequence is that you cannot simply check one enzyme pathway and assume you’re safe; the drug touches multiple systems at once.

The QT Prolongation Problem

The most talked-about hydroxychloroquine interaction involves the heart, specifically the QT interval. Hydroxychloroquine is structurally similar to quinidine, a class IA antiarrhythmic drug that blocks sodium and potassium channels in cardiac cells. This similarity means hydroxychloroquine can slow the heart’s electrical recovery between beats, prolonging the QT interval and raising the risk of a dangerous rhythm disturbance called torsades de pointes.³

On its own, hydroxychloroquine’s QT-prolonging effect is relatively modest at standard doses. The danger ramps up when it is combined with other drugs that also stretch the QT interval. The combination that drew the most scrutiny was hydroxychloroquine plus azithromycin, prescribed widely during the early months of the COVID-19 pandemic. In one study of COVID-19 patients receiving both drugs, the average corrected QT interval rose from 426 milliseconds before treatment to 450 milliseconds after, and four patients exceeded 480 milliseconds, a threshold that signals meaningful cardiac risk.⁴ Whole-heart mapping experiments confirmed that the combination produced QT prolongation, action-potential-duration alternans (beat-to-beat variations in the heart’s electrical behavior), and spatial dispersion of electrical signals, all of which are precursors to arrhythmias.⁵

Azithromycin is far from the only offender. Many commonly prescribed drugs also prolong the QT interval, and combining any of them with hydroxychloroquine can amplify the risk. Examples include certain antidepressants (citalopram, escitalopram), antipsychotics (haloperidol, quetiapine), anti-nausea medications (ondansetron), fluoroquinolone antibiotics (levofloxacin, moxifloxacin), and methadone. For patients managing opioid use disorder with methadone, or those treating tuberculosis with fluoroquinolones, adding hydroxychloroquine calls for careful QT monitoring.⁶ In clinical practice, a baseline electrocardiogram before starting hydroxychloroquine alongside any QT-prolonging medication is standard, with follow-up ECGs to catch any dangerous changes. Critical thresholds generally used include a QTc reaching or exceeding 500 milliseconds, or increasing by 60 milliseconds or more from baseline.⁷

Methotrexate Levels Can Climb

Hydroxychloroquine and methotrexate are frequently prescribed together for rheumatoid arthritis. This combination is considered a standard treatment approach, yet research in rats has shown that hydroxychloroquine significantly increases methotrexate exposure. After multiple doses, animals receiving both drugs had higher peak plasma methotrexate concentrations, higher overall methotrexate exposure, and higher levels of methotrexate inside red blood cells compared to those receiving methotrexate alone. The clearance rate of methotrexate also dropped significantly.⁸

What this means in practice is still being worked out. In many clinical settings, rheumatologists view the combination as effective and generally well-tolerated, and it is possible that the increased methotrexate exposure actually contributes to the combination’s therapeutic benefit. But it also raises the question of whether some patients on both drugs may be getting a larger effective dose of methotrexate than intended, which could explain occasional cases of unexpectedly elevated liver enzymes or lower blood counts. If you are on both medications and your doctor orders blood work more frequently than you expect, this interaction is one reason why.

Retinal Toxicity and Tamoxifen

Long-term hydroxychloroquine use carries a well-known risk of retinal damage, and certain drugs make that risk worse. Tamoxifen, used primarily for breast cancer treatment and prevention, is identified as a factor that independently increases the risk of hydroxychloroquine-related retinal toxicity.⁹ The mechanism is not entirely clear, but tamoxifen itself can cause retinal toxicity, so the two drugs together may be hitting the retina from multiple directions.

Updated screening guidelines from the American Academy of Ophthalmology identify dose, duration of use, concurrent kidney disease, tamoxifen use, and older age at the time hydroxychloroquine is started as the main risk factors for retinopathy.⁹ If you take hydroxychloroquine and tamoxifen together, your ophthalmologist will likely want to screen you more often and may recommend starting screening earlier than the usual five-year mark. This is a case where the interaction is not about blood levels of either drug changing, but about additive damage to the same organ.

Kidney Function Changes the Equation

Hydroxychloroquine is partially cleared by the kidneys, so impaired kidney function raises the concern that the drug could accumulate. Interestingly, a study in Japanese lupus patients found that renal impairment itself did not significantly affect the total clearance of hydroxychloroquine. Instead, co-administration of prednisolone and older age were the factors that mattered more for clearance.¹⁰ That study concluded that dose reduction based solely on kidney function was not necessary for lupus patients.

However, that finding does not mean kidneys are irrelevant to the picture. A case report of hydroxychloroquine-induced renal phospholipidosis, a condition where the drug causes lipid buildup in kidney cells, raised the question of how severe kidney impairment might worsen the risk of this kind of tissue damage, and the authors stressed that hydroxychloroquine should be used cautiously in patients with kidney insufficiency.¹¹ The screening guidelines for retinopathy also list renal disease as a risk factor for eye damage, likely because even modest accumulation of hydroxychloroquine over years could push tissue concentrations into a toxic range.⁹ The practical takeaway is that kidney disease may not dramatically change drug levels in blood, but it might still matter for drug accumulation in specific tissues. Your doctor likely accounts for this when deciding your dose and monitoring schedule.

Vaccines May Not Work as Well

Hydroxychloroquine and its close relative chloroquine can blunt the immune response to certain vaccines. The clearest evidence comes from rabies vaccination. A landmark study showed that people taking chloroquine for malaria prevention who received intradermal rabies vaccine had significantly lower neutralizing antibody levels on every testing day compared to controls, although both groups did reach protective levels by later visits.¹² A more recent study confirmed that chloroquine reduced antibody levels after intramuscular rabies vaccination at certain time points, while other antimalarials like atovaquone-proguanil and doxycycline did not have the same effect.¹³

These studies used chloroquine rather than hydroxychloroquine, but the drugs are pharmacologically similar enough that the concern extends to hydroxychloroquine. The mechanism likely involves the drug’s ability to alter the pH inside immune cells, interfering with how they process and present vaccine components. For most routine vaccines this is probably a minor issue, but for people relying on vaccines with narrow protective margins, such as travelers needing rabies pre-exposure prophylaxis, it is worth discussing timing with your doctor. When possible, completing a vaccine series before starting hydroxychloroquine, or using the intramuscular rather than intradermal route for certain vaccines, may help preserve the immune response.

Seizure Threshold and Neurological Drugs

Hydroxychloroquine can lower the seizure threshold, and in overdose, seizures are a recognized toxic effect.¹⁴ For people taking antiepileptic medications, this creates a potential conflict: hydroxychloroquine may partly counteract the seizure-preventing effect of those drugs. This does not mean the combination is automatically unsafe, but neurologists typically want to know about it so they can monitor seizure frequency and adjust antiepileptic doses if needed.

Psychosis has also been reported as a neurotoxic effect, so the interaction picture with psychiatric medications can be complex.¹⁴ Someone taking an antipsychotic that also prolongs the QT interval faces a double concern: additive cardiac risk and the possibility that hydroxychloroquine could worsen the psychiatric condition the antipsychotic is managing. These scenarios are uncommon but worth flagging with every prescriber involved in your care.

Biologic Therapies and Anti-TNF Agents

In rheumatoid arthritis, hydroxychloroquine is sometimes added to a biologic medication such as an anti-TNF agent. Research on this combination suggests that adding hydroxychloroquine does not increase discontinuation rates of the biologic and may actually improve how long patients stay on certain anti-TNF drugs. One study found that patients who took hydroxychloroquine alongside etanercept or infliximab had longer drug survival on those biologics compared to patients on the biologic alone, and the benefit was comparable to adding methotrexate.¹⁵

This is one of the rare cases where the “interaction” between hydroxychloroquine and another medication appears to be beneficial rather than harmful. The mechanism is probably immunological: hydroxychloroquine may reduce the formation of anti-drug antibodies that cause biologics to lose effectiveness over time. For patients who cannot tolerate methotrexate, hydroxychloroquine offers an alternative concomitant therapy that helps protect their investment in biologic treatment.

Genetic Variation in How You Process the Drug

Not everyone metabolizes hydroxychloroquine the same way. Genetic differences in the CYP2D6, CYP2C8, and CYP3A5 enzymes can significantly alter how fast or slow your body breaks down the drug. People who are ultra-rapid metabolizers may clear hydroxychloroquine so quickly that it never reaches effective levels, leading to therapeutic failure. At the other end, poor metabolizers may accumulate dangerously high levels, increasing the risk of toxicity.¹⁶

The distribution of these metabolizer types varies across ethnic groups, meaning a considerable proportion of patients worldwide may be at risk of either under-treatment or serious side effects without knowing it.¹⁶ This genetic variability also compounds the drug interaction problem. If you happen to be a poor CYP2D6 metabolizer and then add a drug that further inhibits CYP3A4, you could end up with hydroxychloroquine levels far higher than anyone intended. Pharmacogenomic testing is not yet routine for hydroxychloroquine, but it is an area where precision prescribing could make a real difference, particularly for patients who experience unusual side effects or fail to respond at standard doses.

Prednisolone and Corticosteroid Co-administration

Many patients on hydroxychloroquine for autoimmune disease also take corticosteroids. A pharmacokinetic study in lupus patients identified co-administration of prednisolone as a factor that affected the total clearance of hydroxychloroquine, separate from kidney function or other variables.¹⁰ The direction and magnitude of this effect were not fully characterized in that study, but the finding is relevant because corticosteroid dose adjustments are so common in lupus management. Every time a prednisone taper begins or a dose is bumped up during a flare, the effective level of hydroxychloroquine in your system could shift modestly as well. This is generally manageable, but it is one more reason why consistent monitoring is part of long-term hydroxychloroquine therapy.

Effects on the Gut Microbiome

An emerging area of interest is how hydroxychloroquine alters the community of bacteria and other organisms in the gut. Animal research has shown that hydroxychloroquine changes the composition of the gut microbiome, increasing certain beneficial species such as Lactobacillus murinus while decreasing others like Oscillibacter and members of the Bacteroidetes group.¹⁷ Because the gut microbiome itself influences how many oral medications are absorbed and metabolized, this effect could create a secondary layer of drug interactions that has barely been explored. A shift in gut bacteria might subtly change how well you absorb a completely unrelated medication taken by mouth. This is speculative territory at this point, but it fits into a broader picture of hydroxychloroquine as a drug with far-reaching effects beyond its intended immune targets.

Digoxin and P-glycoprotein-Dependent Drugs

Digoxin, a heart medication used for atrial fibrillation and heart failure, relies heavily on P-glycoprotein for its elimination from the body. Since hydroxychloroquine inhibits P-gp at sufficiently high concentrations,² combining the two can raise digoxin levels. Digoxin has a narrow therapeutic window, meaning the difference between an effective dose and a toxic dose is slim. Even a modest increase in digoxin blood levels can produce nausea, visual disturbances, and dangerous heart rhythms. Doctors typically monitor digoxin levels more closely when hydroxychloroquine is on board. The same principle applies to other drugs that depend on P-gp for clearance, though digoxin is the most clinically consequential example because of how little room there is for error.

The transporter interactions of hydroxychloroquine do not end with P-gp. Its inhibition of OATP1A2 could theoretically affect the uptake of drugs that use that transporter to enter the liver or other tissues.¹ The clinical significance of the OATP1A2 interaction in particular is still uncertain, but the broader point is that hydroxychloroquine’s interaction profile involves transporters as well as enzymes, and checking only enzyme-based interaction databases may miss transport-mediated issues.

Keeping Track When You Take Multiple Medications

People who take hydroxychloroquine often take it for years, and their medication lists change over time. A new antibiotic prescribed for a sinus infection, a change in psychiatric medication, a supplement added after a blood test result: each addition to the list is a moment where an interaction could appear. The challenge is that many of these interactions are not dramatic. They do not cause immediate symptoms. Instead, they slowly shift hydroxychloroquine levels higher or lower, or gradually increase risk to the heart or eyes in ways that only show up on monitoring tests.

The most important thing you can do is make sure every prescriber and every pharmacist sees your full medication list, including over-the-counter drugs and supplements. Pharmacists are often the best-positioned people to catch drug interactions because they see the whole picture across all your prescribers. If you are on hydroxychloroquine long-term and a new medication is added, asking specifically about QT prolongation and enzyme interactions is reasonable. And if you start experiencing new symptoms, whether nausea, visual changes, palpitations, or unusual fatigue, a drug interaction should be on the list of possible explanations.

1
PubMed Central. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters
2
PubMed Central. Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters
3
PubMed Central. Hydroxychloroquine and the associated risk of arrhythmias
4
PubMed Central. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin
5
Heart Rhythm O2. Quantifying arrhythmic long QT effects of hydroxychloroquine and azithromycin with whole-heart optical mapping and simulations
6
Scientific Reports. Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice
7
PubMed Central. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring
8
PubMed Central. Hydroxychloroquine increases the exposure of methotrexate in plasma and red blood cells: a pharmacokinetic interaction study in rats in vivo
9
PubMed. Special AAO Report: Recommendations on Screening for Hydroxychloroquine Retinopathy (2025 Revision)
10
Modern Rheumatology. Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment
11
PubMed Central. Hydroxychloroquine-Induced Renal Phospholipidosis: Case Report and Review of Differential Diagnoses
12
PubMed. Antibody Response to Preexposure Human Diploid-Cell Rabies Vaccine Given Concurrently with Chloroquine
13
The Journal of Infectious Diseases. Effect of Antimalarial Drugs on the Immune Response to Intramuscular Rabies Vaccination Using a Postexposure Prophylaxis Regimen
14
PubMed. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose
15
Arthritis & Rheumatology. Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis
16
PubMed. Pharmacogenomics of chloroquine and hydroxychloroquine: current evidence and future implications
17
PubMed Central. Effects of hydroxychloroquine on the mucosal barrier and gut microbiota during healing of mice colitis